EP2481813A1 — Markers of cutaneous melanoma and uses thereof
Assigned to Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano · Expires 2012-08-01 · 14y expired
What this patent protects
The invention relates to a method for determining prognosis, predicting or monitoring response to therapy of patients affected by cutaneous melanoma through the evaluation of the methylation of different genomic DNA sequences, including the Long Interspersed Nucleotide Element-1 …
USPTO Abstract
The invention relates to a method for determining prognosis, predicting or monitoring response to therapy of patients affected by cutaneous melanoma through the evaluation of the methylation of different genomic DNA sequences, including the Long Interspersed Nucleotide Element-1 ( LINE-1 ) repetitive DNA sequences and/or the concomitant methylation profile of specific groups of genes defined as methylation signature.
Drugs covered by this patent
- Vidaza (azacitidine) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.